LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: CCR10-mediated Enhancement of T Cell Trafficking for Improved Tumor Immunotherapy.

    Hong, Jong Moo / Jeong, Byung-Kwan / Han, Doyeon / Kim, Kwanghee / Lee, In Won / Hong, Chorong / Lee, Gunhee / Gong, Gyungyub / Lee, Hee Jin

    Anticancer research

    2024  Volume 44, Issue 2, Page(s) 521–532

    Abstract: Background/aim: The effectiveness of adoptive T cell therapy for solid tumors remains suboptimal, partly attributed to insufficient T cell infiltration into the tumor site. A promising strategy involves directing T cells towards the tumor utilizing ... ...

    Abstract Background/aim: The effectiveness of adoptive T cell therapy for solid tumors remains suboptimal, partly attributed to insufficient T cell infiltration into the tumor site. A promising strategy involves directing T cells towards the tumor utilizing tumor-specific chemokine receptors.
    Materials and methods: We analyzed chemokine receptor expression in activated T cells and chemokine expression in breast and lung cancer using The Cancer Genome Atlas (TCGA) data. Subsequently, we generated 1G4 T cell receptor-engineered T (TCR-T) cells with CCR10 and performed in vitro and in vivo efficacy tests.
    Results: CCR10 exhibited insufficient expression in various human T cells. Analysis of TCGA RNA sequencing data revealed elevated expression of the chemokine CCL28, the corresponding chemokine for CCR10, in breast and lung cancer. Consequently, we generated CCR10-1G4 TCR-T cells. CCR10-1G4 dual expressing TCR-T cells exhibited comparable cellular cytotoxicity but increased mobility compared to 1G4 TCR-T cells in vitro. Furthermore, injecting CCR10-1G4 dual expressing TCR-T cells into a xenograft tumor model demonstrated enhanced in vivo trafficking and a greater reduction of tumor burden.
    Conclusion: This study highlights the potential of CCR10 for developing efficient adoptive T-cell treatments targeting solid tumors.
    MeSH term(s) Humans ; T-Lymphocytes/metabolism ; Chemokines/metabolism ; Receptors, Chemokine ; Immunotherapy ; Lung Neoplasms/therapy ; Receptors, Antigen, T-Cell/genetics ; Receptors, CCR10/genetics ; Receptors, CCR10/metabolism
    Chemical Substances Chemokines ; Receptors, Chemokine ; Receptors, Antigen, T-Cell ; CCR10 protein, human ; Receptors, CCR10
    Language English
    Publishing date 2024-02-01
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.16840
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1.

    Jeon, Bu-Nam / Kim, Hye-Ran / Chung, Yun Shin / Na, Bo-Ra / Park, Hyunkyung / Hong, Chorong / Fatima, Yasmin / Oh, Hyeonju / Kim, Chang-Hyun / Jun, Chang-Duk

    Oncoimmunology

    2018  Volume 7, Issue 12, Page(s) e1500674

    Abstract: Correct temporal and spatial control of actin dynamics is essential for the cytotoxic T cell effector function against tumor cells. However, little is known whether actin engineering in tumor-targeted T cells can enhance their antitumor responses, ... ...

    Abstract Correct temporal and spatial control of actin dynamics is essential for the cytotoxic T cell effector function against tumor cells. However, little is known whether actin engineering in tumor-targeted T cells can enhance their antitumor responses, thereby potentiating the adoptive T cell therapy. Here, we report that TAGLN2, a 22-KDa actin-stabilizing protein which is physically associated with lymphocyte function-associated antigen-1 (LFA-1), potentiates the
    Language English
    Publishing date 2018-09-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2645309-5
    ISSN 2162-402X ; 2162-4011
    ISSN (online) 2162-402X
    ISSN 2162-4011
    DOI 10.1080/2162402X.2018.1500674
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top